Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Navlimetostat in Japanese and Chinese Participants With Advanced Solid Tumors With Homozygous MTAP Deletion
NCT07077434Phase 1Recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Oct 2025
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of navlimetostat in solid tumor, sponsored by Bristol Myers Squibb. Primary endpoints: Maximum Plasma Concentration, Time to Reach Maximum Plasma Concentration and 4 more. Started Oct 2025; status: recruiting.
02
Drugs
navlimetostat
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07077434.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07077434.